Piramal Enterprises has been granted a patent for a pharmaceutical combination to treat melanoma. The kit includes a CDK inhibitor and an anticancer agent like a BRAF or MEK inhibitor. The method involves administering these agents to a patient. GlobalData’s report on Piramal Enterprises gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Piramal Enterprises Ltd - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Piramal Enterprises, Cancer treatment biomarkers was a key innovation area identified from patents. Piramal Enterprises's grant share as of January 2024 was 35%. Grant share is based on the ratio of number of grants to total number of patents.

Pharmaceutical kit for melanoma treatment with cdk inhibitor

Source: United States Patent and Trademark Office (USPTO). Credit: Piramal Enterprises Ltd

A pharmaceutical kit for the treatment of melanoma has been granted a patent, as per Publication Number US11839591B2. The kit includes a CDK inhibitor of Formula I or a pharmaceutically acceptable salt, along with various anticancer agents such as vemurafenib, dabrafenib, and trametinib. The kit provides instructions for simultaneous or sequential administration of the CDK inhibitor and the anticancer agents to individuals with non-refractory, metastatic, or recurrent/refractory melanoma, including specific BRAF mutant melanoma subtypes like BRAFV600E or BRAFV600K mutant melanoma.

Furthermore, the pharmaceutical kit may contain a fixed dose formulation of the CDK inhibitor and anticancer agents in a single container or separate containers. The package insert includes comprehensive information on indications, usage, doses, administration directions, contraindications, precautions, and warnings. Additionally, the kit may also include a container with a pharmaceutically acceptable buffer, water for injection, phosphate-buffered saline, Ringer's solution, or dextrose solution to facilitate administration. This patent aims to provide a structured and effective treatment approach for melanoma, particularly targeting specific BRAF mutant melanoma subtypes, with detailed guidance for healthcare professionals and patients on the usage and administration of the pharmaceutical kit.

To know more about GlobalData’s detailed insights on Piramal Enterprises, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies